Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | CCR9 | P51686 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756685 | 0.80 | POLB (0.68) | POLBABCB11CCR9MAPTKDM1A | |
| SCHEMBL14975727 | 0.77 | MAPT (0.74) | POLBABCB11CCR9MAPTTHRB | |
| SCHEMBL4109131 | 0.77 | POLB (0.63) | POLBABCB11CCR9MAPTKDM1A | |
| SCHEMBL12583930 | 0.74 | ABCB11 (0.79) | POLBABCB11CCR9MAPTTHRB | |
| SCHEMBL2400013 | 0.73 | CCR2 (0.63) | POLBTSHRALDH1A1L3MBTL1 | |
| SCHEMBL7673214 | 0.71 | ABCB11 (1.00) | POLBABCB11CCR9MAPTTHRB | |
| SCHEMBL29843471 | 0.71 | POLB (0.56) | POLBABCB11CCR9MAPTKDM1A | |
| SCHEMBL3766716 | 0.71 | KDM1A (0.64) | POLBCCR9MAPTKDM1ARCOR1 | |
| SCHEMBL28043181 | 0.71 | CCR9 (0.44) | CCR9 | |
| SCHEMBL3276177 | 0.70 | POLB (0.54) | POLBABCB11CCR9MAPTKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | POLB 3160/4885ABCB11 282/4885CCR9 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.